Paraoxonase-1 gene in patients with chronic obstructive pulmonary disease investigation Q192R and L55M polymorphisms

doi:10.5847/wjem.j.1920-8642.2015.03.007

Abstract

Abstract:

BACKGROUND: The effect of increased oxidative stress on the development of chronic obstructive pulmonary disease (COPD) is well known. One of the antioxidative systems against oxidative stress in human body is paraoxonase (PON) enzyme that protects low density lipoproteins (LDL) against oxidation. This study aimed to explore the polymorphisms on PON1, Q192R, L55M genes of patients with COPD.
METHODS: DNAs extraction was obtained from blood samples of 50 patients diagnosed with COPD and 50 patients as a control group who were presented to emergency clinic. Genotypes were obtained with polymerase chain reaction (PCR) and AIw I and Hsp92II restriction enzymes were used for Q192R and L55M polymorphisms, respectively. Analysis of data was done with the Chi-square test and Fisher's exact test.
RESULTS: A statistically significant difference in Q192R polymorphism was found between the COPD patients and the control group (P=0.05). There was no statistically significant difference in L55M polymorphisms between the patient and control groups (P>0.05). Q192R polymorphism was significantly correlated with the PON1 gene and cigarette smoking; however other risk factors did not show any significant correlation with this polymorphism. Though L55M polymorphism was significantly correlated with family history and tuberculosis, there was no significant correlation with other risk factors.
CONCLUSION: We believe that more studies are needed to study the correlation of L55M polymorphism with other factors.

Key words: Chronic obstructive pulmonary disease, Paraoxonase, Polymorphism, Acute attack

Şükrü Gürbüz, Mustafa Yıldız, Murat Kara, Kürşat Kargün, Mehtap Gürger, Metin Ateşçelik, Ömer Doğan Alataş. Paraoxonase-1 gene in patients with chronic obstructive pulmonary disease investigation Q192R and L55M polymorphisms[J]. World Journal of Emergency Medicine, 2015, 6(3): 201-206.

Figures/Tables 9

Figure 1.

Figure 2.

Table 1

Table 2

Table 3

Table 4

Table 5

Table 6

Table 7

References 24

1	William MN. Oxidants/Antioxidants and COPD. Chest 2000; 117:303-317. pmid: 10669665
2	Tekes S, Isik B, Yildiz T, Simsek S, Isik MR, Budak T. Chronic Obstructive Pulmonary Disease and Paraoxonase-1 192 And 55 Gene Polymorphisms. Biotechnol & Biotechnol 2010; 24:1644-1647.
3	Mackness MI, Arrol S, Durington PN. Paraoxonase prevents accumulation of lipoperoxides in low density lipoprotein. FEBS Lett 1991; 286:152-154.
4	Rousselot DB, Therond P, Beaudeux JL, Peynet J, Legrand A, Delatre J. High density lipoproteins and the oxidative hypothesis of atherosclerosis. Clin Chem Lab Med 1999; 37:939-949. doi: 10.1515/CCLM.1999.139 pmid: 10616747
5	Bauera M, Gräbsch C, Schlink U, Klopp N, Illig T, Krämer U, et al. Genetic association between obstructive bronchitis and enzymes of oxidative stress. Metabolısm: Clınıcal and Experımental 2012; 61:1771-1779.
6	Stanojkovic I, Stevuljevic JK, Milenkovic B, Spasic S, Vujic T, Stefanovic A, et al. Pulmonary function, oxidative stress and inflammatory markers in severe COPD exacerbation. Respiratory Medicine 2011; 105:31-37.
7	Arphana V, Ehtesham A, Desh D. Genetic polymorphisms of GSTP1 and MEPHX correlate with oxidative stres markers and lung function in COPD. BBRC 2007; 359:136-142.
8	Ehtesham A, Arpana V, Pervz A. Association of CYP2E1 and NAT2 gene polymorphisms with chronic obstructive pulmonary disease. Clinica Chimica Acta 2007; 382:37-42.
9	Charlotte ER, Maureen CH, Martin T. Tumor necrosis factor gene complex polymorphisms in chronic obstructive pulmonary disease. Respiratory Medicine 2007; 101:340-344.
10	Li HL, Liu DP, Liang CC. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 2003; 81:766-779. doi: 10.1007/s00109-003-0481-4
11	Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon Br J Pharmacol 1997; 122:265-268.
12	Hersh CP, Hokanson JE, Lynch DA, Washko GR, Make BI, Crapo JD, et al. Family history is a risk factor for chronic obstructive pulmonary disease. Chest 2011; 140:343-350. pmid: 21310839
13	Orhan Z, Köksal N, Gökırmak M, Hacıevliyagil S, Hasanoğlu HC, Mehmet N, et al. Oxidative stress in acute exacerbations of copd and the effect of therapy on oxidant-antioxidant balance. Respiratory Diseases 2003; 14:5-10.
14	Christopher ADS, David JH. Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 1997; 350:630-633. doi: 10.1016/S0140-6736(96)08061-0 pmid: 9288046
15	Mannino DM, Homa DM, Akinbami LJ. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR Surveill Summ 2002; 51:1-16. pmid: 12004983
16	Menezes AM, Perez-Padilla P, Jardim JR. Chronic obstructive pulmonary disease in five Latin American cities (the PLATİNO study): a prevalence study. Lancet 2005; 366:1875-1881. pmid: 16310554
17	Ben-Selma W, Harizi H, Bougmiza I, Ben Kahla I, Letaief M, Boukadida J. Polymorphisms in the RANTES gene increase susceptibility to active tuberculosis in Tunisia. DNA Cell Biol 2011; 30:789-800. pmid: 21510799
18	Han M, Yue J, Lian YY, Zhao Y, Wang H, Liu LR. Relationship between single nucleotide polymorphism of interleukin-18 and susceptibility to pulmonary tuberculosis in the Chinese Han population. Microbiol Immunol 2011; 55:388-393. doi: 10.1111/j.1348-0421.2011.00332.x pmid: 21395662
19	Hahn DL. Chlamydia pneumoniae, asthma, and COPD: what is the evidence? Ann Allergy Asthma Immunol 1999; 83:271-288. pmid: 10541419
20	Repine EJ, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156:341-357. pmid: 9279209
21	George BR, San Pedro SG. Chronic obstructive pulmonary disease: Clinical course and management. Fishman AP, (ed). Fishman's Pulmonary Diseases and Disorders. 3rd ed. New York: McGraw Hill Company 1998; 683-696.
22	Serhat Erol, Aydın Çiledağ, Akın Kaya, Salih Cesur, Yasemin Fidan, Sami Kınıklı, et al. The diagnostic value of pleural fluid neopterin level in tuberculous pleurisy. Turkish Thoracic Journal 2010; 11:62-65.
23	Chapman KR, Mannino DM, Soriano N. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006; 27:188-207. pmid: 16387952
24	Rajković MG, Barišić K, Juretić D, Grubišić TŽ, Flegar-Meštrić Z, Rumora L. Polymorphisms of PON1 and PON2 genes in hemodialyzed patients. Clin Biochem 2011; 44:964-968.

Variables	COPD (n=55)	Control (n=50)
Age (years)	68.92±10.76	50.54±11.80
Sex (Male/Female)	38/17	32/18

Variables	COPD (n, %))	Control (n, %))
Family history	15 (7.3)	2 (4.0)
Smoking	35 (36.6)	20 (40.0)
Asbestosis	0 (0)	0 (0)
Tbc	4 (7.3)	1 (2.0)
Respiratory tract infections	23 (41.8)	1 (2.0)
Socioeconomic status	9 (16.4)	1 (2.0)
Nutrition	8 (14.5)	0 (0)

Groups	n	QQ (n, %)	QR (n, %)	RR (n, %)
COPD patients	51	33 (64.7)	14 (27.5)	4 (7.8)
Controls	40	32 (80.0)	8 (20.0)	0 (0)
P value	0.05

Groups	n	LL (n, %)	LM (n, %)	MM (n, %)
COPD patients	49	30 (61.2)	18 (36.7)	1 (2. 0)
Controls	42	25 (59.5)	17 (40.5)	0 (0)
P value	0.05

Gene	Genotype Allele	Patients (n=51)	Controls (n=40)	χ²	P
PON1 gene Q192R	QQ	33 (0.647)	32 (0.800)	4.386	0.111
	QR	14 (0.275)	8 (0.200)
	RR	4 (0.078)	0 (0.000)
	Q	80 (0.784)	72 (0.900)	4.358	0.036
	R	22 (0.216)	8 (0.100)	4.358	0.036
PON1 gene L55M	LL	30 (0.612)	25 (0.595)	0.950	0.621
	LM	18 (0.367)	17 (0.405)
	MM	1 (0.020)	0 (0.000)
	L	78 (0.796)	67 (0.798)	0.0008	0.977
	M	20 (0.204)	17 (0.202)	0.0008	0.977